期刊文献+

盐酸齐拉西酮对精神病患者血脂代谢的影响 被引量:2

下载PDF
导出
摘要 盐酸齐拉西酮是近几年新上市的非典型广谱抗精神病药,我们对应用盐酸齐拉西酮的精神病患者的血脂代谢情况进行了跟踪对照研究,以探讨其对患者血脂代谢的影响,报告如下。选取2009年3月至2011年3月在我院接受住院治疗,出院后继续门诊治疗的首发精神分裂症患者为研究对。
出处 《山西医药杂志(上半月)》 CAS 2011年第12期1241-1242,共2页 Shanxi Medical Journal
  • 相关文献

参考文献5

二级参考文献14

  • 1司天梅,舒良,于欣,马崔,王高华,白培深,刘协和,纪丽萍,师建国,陈宪生,梅其一,栗克清,张鸿燕,马弘.10省市抗精神病药使用现况的调查[J].中华精神科杂志,2004,37(3):152-155. 被引量:95
  • 2张苏明,梅爱农.代谢综合征、胰岛素抵抗与脑血管疾病[J].中华神经科杂志,2004,37(5):468-470. 被引量:30
  • 3陈灏珠 李宗明 主编.内科学:第4版[M].北京:人民卫生出版社,1998.120.
  • 4Jin H, Meyer JM, Jeste DV. Atypical antipsychoties and glucose dysregulation: a systematic review. Schizophr Res, 2004, 71:195-212.
  • 5陈灏珠,主编.实用内科学.七册.第11版.北京:人民卫生出版社,2001.955-962.
  • 6李绍魁,高航云,主编.临床常用治疗数据手册修订本.第2版.郑州:河南科技出版社,2001,67-69.
  • 7Baptista T, Kin NM, Beaulieu S, et al. Obesity and related metabolic abnormalities during antipsychotic drug administration:mechanisms, management and research perspectives.Pharmacopsychiatry, 2002, 35:205-219.
  • 8Expert Panel. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection,evaluation, and treatment of high blood cholesterol in adults ( Adult Treatment Panel Ⅲ ). JAMA, 2001 , 285:2486-2497.
  • 9American Diabetes Association, American Psychiatric Association,American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry, 2004, 65:267-272.
  • 10Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics : an analysis of 45 published cases. Ann Clin Psychiatry, 2002, 14:59-64.

共引文献48

同被引文献23

  • 1中华医学会糖尿病学分会代谢综合征研究协作组.中华医学会糖尿病学分会关于代谢综合征的建议[J].中国糖尿病杂志,2004,12(3):156-161. 被引量:3058
  • 2Sachet J, Mossaheb N, Spindelegger C, et al. Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers[J]. Neuropsy- chopharmacology,2008,33: 1 633 - 1 641.
  • 3Brown RR, Estoup MW. Comparison of the metabolic effects observed in patients treated with ziprasidone versus olan[J]. International Clinical Psychopharmacology,2005,20(2): 105 - 112.
  • 4Rettenhaeherl MA, Ebenbichler C, Hofer A, et al. Alterations of glu- cose metabolism in patients treated with ziprasidone vsclozapine[J] . Schizophrenia Research, 2010,117 (2) : 506.
  • 5Emilio S, Alessandro G, Paolo V, et al. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: The MOZART study [ J ]. Schizophrenia Research,2009,113:112 - 121.
  • 6Stip E, Zhornitsky S, Moteshafi H, et al. Ziprasidone for psychotic disor- ders: a meta - analysis and systematic review of the relationship between pharmacokinetics, pharmacodynamics, and clinical profile[J] . Clinical Therapeutics, 2011,33 (12) : 1 853 - 1 867.
  • 7Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia[J]. The New England Journal of Medicine,2005, 353:1 209- 1 223.
  • 8Dragasek J, Paloval E, Lukacsova I, et al. Lipid metabolism changes after switching to ziprasidone [ J ]. European Psychiatry, 2010,25 ( 1 ) : 1 713.
  • 9陈青,刘小林,陈友芝.奥氮平与齐拉西酮对老年痴呆患者糖脂代谢的影响[J].卒中与神经疾病,2008,15(6):369-371. 被引量:12
  • 10田爱军,李忠玲,赵淑君,金佳华.齐拉西酮对精神病人糖代谢的影响研究[J].中国现代医生,2009,47(8):91-92. 被引量:5

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部